Microbiome-Based Therapy Gains FDA Fast Track in Ulcerative Colitis

FDA has granted fast track designation to MH002, an investigational microbiome-based therapy developed by Belgium-based MRM Health, a clinical-stage biopharmaceutical company, for treating mild-to-moderate ulcerative colitis (UC). The designation reflects regulatory recognition of the therapy’s potential to address unmet medical need in a chronic inflammatory disease for which durable remission remains difficult to achieve.¹

UC, a form of inflammatory bowel disease (IBD), is characterized by persistent inflammation of the colon and can significantly impact quality of life. While multiple treatment options exist, many patients with mild-to-moderate disease do not achieve sustained remission or require escalation to systemic immunosuppressive therapies, highlighting the need for alternative approaches.²

What distinguishes microbiome-based therapies like MH002 in UC?

MH002 is described as a rationally designed live biotherapeutic product composed of a consortium of six well-characterized commensal bacterial strains. Unlike traditional therapies that suppress immune responses, MH002 is designed to restore microbial balance and modulate immune function within the gut, according to the company.

This mechanism represents a growing area of interest in drug development, for which the microbiome is increasingly recognized as a potential therapeutic target in immune-mediated diseases. By aiming to address underlying disease biology rather than symptoms alone, such approaches may offer a differentiated strategy compared with conventional anti-inflammatory or immunosuppressive treatments.³

“[FDA’s] decision to grant [f]ast [t]rack designation to MH002 recognizes the potential of this promising [l]ive [b]iotherapeutic [p]roduct to address the significant unmet need for innovative and more effective therapies for patients with ulcerative colitis,” said Sam Possemiers, PhD, CEO, MRM Health, in a company press release.¹

How do early clinical data support MH002 development?

The fast track designation is supported by findings from a phase 2a clinical trial, which demonstrated a favorable safety profile and early signals of efficacy. Reported outcomes included improvements in mucosal healing, restoration of microbiome balance, and induction of clinical remission, with no significant adverse reactions observed.

Building on these results, MRM Health is advancing MH002 into a phase 2b study, known as STARFISH-UC, which is expected to enroll approximately 204 patients across Europe and the United States. The trial is designed to further evaluate efficacy and safety in patients whose disease is inadequately controlled by standard first-line therapies.

The progression of MH002 into later-stage development highlights increasing investment in microbiome-based therapeutics, an emerging modality that has faced historical challenges related to manufacturing consistency, regulatory pathways, and clinical validation.³

What are the broader implications of fast track designation for microbiome therapeutics?

Fast track designation is intended to facilitate the development and expedite the review of therapies that address serious conditions and unmet medical needs. Benefits include more frequent interactions with regulators, eligibility for rolling review, and potential qualification for accelerated approval or priority review.¹

For microbiome-based therapies, regulatory recognition may signal increasing acceptance of this modality within established drug development frameworks. This acceptance could influence future investment and pipeline expansion in the field, particularly as companies seek to translate advances in microbiome science into clinically validated treatments.³

MRM Health is developing MH002 using its proprietary platform, which is designed to produce multi-strain bacterial consortia at scale. The company’s approach reflects broader efforts to harness microbial ecosystems as therapeutic agents across a range of inflammatory and immune-related diseases.

While the designation may accelerate MH002’s development timeline, further clinical data will be required to confirm its efficacy and long-term safety. For now, the designation highlights a potential shift toward novel therapeutic strategies in UC, for which innovation continues to focus on improving disease control while minimizing systemic side effects.

References

1. MRM Health. MRM Health’s lead candidate MH002 granted fast track designation by US FDA for the treatment of mild-to-moderate ulcerative colitis. Published April 30, 2026. Accessed May 1, 2026. https://mrmhealth.com/docs/20260430_MH002_Fast%20Track%20Designation_ENG.pdf
2. Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers 2020;6:74. doi: 10.1038/s41572-020-0205-x
3. Fitzgibbon G, Mills, KHG. The microbiota and immune-mediated diseases: Opportunities for therapeutic intervention. Eur. J. Immunol. 2020;50(3):326-337. doi: 10.1002/eji.201948322